Patents by Inventor Ernesto Moreno Frias

Ernesto Moreno Frias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant antibodies having dual specificity for gangliosides and use thereof
    Patent number: 9527920
    Abstract: The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: December 27, 2016
    Assignee: CENTRO DE IMMUNOLOGIA MOLECULAR
    Inventors: Ernesto Moreno Frias, Gertrudis Rojas Dorantes, Ana Victoria Casadesus Pazos
  • RECOMBINANT ANTIBODIES HAVING DUAL SPECIFICITY FOR GANGLIOSIDES AND USE THEREOF
    Publication number: 20150093385
    Abstract: The present invention relates to new monoclonal antibodies and fragments of these antibodies, which have dual specificity and high affinity for N-acetyl GM3 and N-glycolyl GM3 and do not recognize other gangliosides. In another aspect, the present invention relates to the use of these antibodies and their fragments in the therapy of tumors characterized by a significant expression of any of the two antigens recognized by these antibodies, or a mixed expression of both antigens. Likewise, the invention relates to the use of these antibodies in the diagnosis of tumors expressing at least one of the two variants of the GM3 ganglioside.
    Type: Application
    Filed: February 21, 2013
    Publication date: April 2, 2015
    Applicant: CENTRO DE INMUNOLOGIA MOLECULAR
    Inventors: Ernesto Moreno Frias, Gertrudis Rojas Dorantes, Ana Victoria Casadesus Pazos
  • Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
    Patent number: 6506883
    Abstract: Humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The humanized and monoclonal antibodies may comprise variable regions of non-human origin and constant regions of human origin with amino acid substitutions with the variable regions and/or framework regions. Use of the antibodies for therapeutical and diagnostic purposes is also disclosed.
    Type: Grant
    Filed: December 21, 1998
    Date of Patent: January 14, 2003
    Assignee: Centro de Inmunologia Molecular
    Inventors: Christina Maria Meteo de Acosta del Rio, Rolando Pérez Rodríguez, Ernesto Moreno Frías
  • HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES THAT RECOGNIZE EPIDERMAL GROWTH FACTOR RECEPTOR (EGF-R); DIAGNOSTIC AND THERAPEUTIC USE
    Publication number: 20020065398
    Abstract: New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin.
    Type: Application
    Filed: December 21, 1998
    Publication date: May 30, 2002
    Inventors: CRISTINA M.M.A. DEL RIO, ROLANDO PEREZ RODRIGUEZ, ERNESTO MORENO FRIAS
  • Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
    Patent number: 5891996
    Abstract: New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence: light chain:CDR-1: arg-ser-ser-gln-asn-ile-val-his-ser-asn-gly-asn-thr-tyr-leu-asp;CDR-2: lys-val-ser-asn-arg-phe-ser;CDR-3: phe-gln-tyr-ser-hys-val-pro-trp-thr.Heavy chain:CDR-1: asn-tyr-tyr-ile-tyr;CDR-2: gly-ile-asn-pro-thr-ser-gly-gly-ser-asn-phe-asn-glu-lys-phe-lys-thr;CDR-3: gln-gly-leu-trp-phe-asp-ser-asp-gly-arg-gly-phe-asp-phe.Use of the antibodies for therapeutical and diagnostic purposes.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: April 6, 1999
    Assignee: Centro de Inmunologia Molecular
    Inventors: Cristina Maria Mateo de Acosta del Rio, Rolando Perez Rodriguez, Ernesto Moreno Frias